Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Dyadic International, Inc. - Common Stock (NQ:DYAI)

1.060 +0.090 (+9.28%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 7, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,120,176
Open	1.000
Bid (Size)	1.060 (900)
Ask (Size)	1.110 (100)
Prev. Close	0.9700
Today's Range	0.9600 - 1.160
52wk Range	0.6546 - 1.346
Shares Outstanding	36,187,798
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential

Today 7:25 EDT

C1 Monoclonal Antibody Progress for RSV and Malaria Following Full $3.1 Million Gates Foundation Grant Funding

From Dyadic International, Inc.

Via GlobeNewswire

Dyadic Expands IP Protection and Business Development Activities in Japan

June 29, 2026

Bolsters Japan Market Expansion, Strategic Collaborations and Demand for Scalable Recombinant Protein Solutions

From Dyadic International, Inc.

Via GlobeNewswire

Performance

YTD	+12.8%	+12.8%
1 Month	+51.6%	+51.6%
3 Month	+20.5%	+20.5%
6 Month	+14.0%	+14.0%
1 Year	+15.8%	+15.8%

More News

Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption

June 15, 2026

From Dyadic International, Inc.

Via GlobeNewswire

Dyadic International Inc (NASDAQ:DYAI) Q1 Report Beats Revenue Expectations but EPS Miss Triggers 28% After-Market Selloff ↗

May 13, 2026

Via Chartmill

Dyadic International Inc (NASDAQ:DYAI) Reports Q4 2025 Earnings Miss, Stock Dips ↗

March 25, 2026

Via Chartmill

Dyadic (DYAI) Q1 2026 Earnings Call Transcript ↗

June 02, 2026

Via The Motley Fool

Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development

May 28, 2026

From Dyadic International, Inc.

Via GlobeNewswire

Dyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor Conference

May 19, 2026

From Dyadic International, Inc.

Via GlobeNewswire

Dyadic to Report Q1 2026 Financial Results and Host Conference Call on Wednesday May 13, 2026

April 29, 2026

From Dyadic International, Inc.

Via GlobeNewswire

Dyadic (DYAI) Q4 2025 Earnings Call Transcript ↗

March 25, 2026

Via The Motley Fool

Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices

March 16, 2026

From Dyadic International, Inc.

Via GlobeNewswire

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

March 13, 2026

From Virtual Investor Conferences

Via GlobeNewswire

Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026

March 11, 2026

From Dyadic International, Inc.

Via GlobeNewswire

Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th

March 10, 2026

From Virtual Investor Conferences

Via GlobeNewswire

Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)

March 04, 2026

From Dyadic International, Inc.

Via GlobeNewswire

Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone

March 02, 2026

From Dyadic International, Inc.

Via GlobeNewswire

Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin

February 17, 2026

From Dyadic International, Inc.

Via GlobeNewswire

Santa’s Rally: CMCT, SURG, SIDU, MYSE, AZI – Stocks Under $5 to Watch Now – More Inside

December 22, 2025

Via AB Newswire

Dyadic and Fermbox Bio Expand Strategic Collaboration to Accelerate Commercialization of Animal-Free Proteins and Enzymes Across Life Science, Food & Nutrition, and Bioindustrial Markets

December 17, 2025

From Dyadic International, Inc.

Via GlobeNewswire

Dyadic Applied BioSolutions Establishes Commercial Partnership to Accelerate Adoption of Dyadic’s Recombinant Growth Factors and Media Proteins

December 15, 2025

From Dyadic International, Inc.

Via GlobeNewswire

Updated Lineup Announced for iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025

December 08, 2025

Via ACCESS Newswire

What's going on in today's after hours session ↗

December 01, 2025

Via Chartmill

iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025

December 01, 2025

Via ACCESS Newswire

Top movers in Monday's pre-market session ↗

December 01, 2025

Via Chartmill

Dyadic and BRIG BIO Sign Development & Commercialization Agreement to Bring Animal-Free Bovine Alpha-Lactalbumin to Global Nutrition Markets

December 01, 2025

From Dyadic International, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Dyadic International, Inc. - Common Stock publicly traded?

Yes, Dyadic International, Inc. - Common Stock is publicly traded.

What exchange does Dyadic International, Inc. - Common Stock trade on?

Dyadic International, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Dyadic International, Inc. - Common Stock?

The ticker symbol for Dyadic International, Inc. - Common Stock is DYAI on the Nasdaq Stock Market

What is the current price of Dyadic International, Inc. - Common Stock?

The current price of Dyadic International, Inc. - Common Stock is 1.060

When was Dyadic International, Inc. - Common Stock last traded?

The last trade of Dyadic International, Inc. - Common Stock was at 07/07/26 04:00 PM ET

What is the market capitalization of Dyadic International, Inc. - Common Stock?

The market capitalization of Dyadic International, Inc. - Common Stock is 38.36M

How many shares of Dyadic International, Inc. - Common Stock are outstanding?

Dyadic International, Inc. - Common Stock has 38M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.